Gilead Powers to New Highs
Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes drugs for life threatening diseases. Their products are Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
.below_low_valuation { background: #2CC822; color: #fff; font-weight: bold; } .low_valuation_5 { background: #BFF2AB; color: #000; font-weight: bold; } .above_high_valuation { background: #D21614; color: #fff; font-weight: bold; } .high_valuation_5 { background: #F28264; color: #000; font-weight: bold; } .stockbox_table { color: #000000; border:none !important; font-family: 'open_sansregular'; } .stockbox_shortcode_table td { text-align: center; vertical-align: middle; padding:5px !important; padding-right:10px !important; } .stockbox_shortcode_table td a{ color:#0066CC !important; text-decoration:none !important; } .stockbox_shortcode_table td a:hover{ color:#0066CC !important; text-decoration:none !important; font-weight:bold !important; } #stock_table_loading { color: #fff; margin-bottom: 5px; text-align: center; } #stock_shortcode_table_us, #stock_shortcode_table_tsx { display:table-row-group; border-collapse: separate !important; border-spacing: 1px !important; font-size: 8px !important; line-height: 15px; } .stockbox_shortcode h3 a { color: #A3CA52; } .lgnd span { margin: 3px; padding: 3px; } .stockbox_shortcode{ background-color:#7151b1; border-radius:6px; width:280px; float:right; margin:0px 10px 10px; } .stockbox_shortcode h3{ color:#fff !important; font-size:15px; padding:10px; padding-bottom:0px; margin: 15px 0px; } .lgnd{ /*background-color:#e7e7e7;*/ /*border-radius: 0px 0px 6px 6px;*/ padding:10px; font-size: 10px; /*color: #000000;*/ } .lgnd hr { margin-top: 5px; margin-bottom: 5px; border:0px; height: 1px; background: transparent; border-top: 1px solid #fff; } .widget_top_picks_stock_widget { list-style:none !important; } var ajaxurl = 'https://purplechips.com/wp-admin/admin-ajax.php ' ; function add_to_watchlist(company_name,storage_symbol,stock_exchange,user_id,attachobj) { jQuery.ajax({ type: 'POST', url: ajaxurl, data: { action : 'add_to_watchlist', ajax : 'true', type : "POST", companyname:company_name, storagesymbol:storage_symbol, stockexchange:stock_exchange, userid:user_id }, success: function(data, textStatus, XMLHttpRequest){ jQuery(attachobj).parent().find('img#add_to').attr('src','https://purplechips.com/wp-content/plugins/pc_graph_plugin/images//watch-icon.png'); jQuery(attachobj).parent().find('img#add_to').attr('title','Symbol Added to YOur Watchlist'); alert(data); }, error: function(MLHttpRequest, textStatus, errorThrown){ alert(1); } }); } function displayGraph(symbol_value,symbol_exchange) { displaySymbolGraph(symbol_value,symbol_exchange); } jQuery(document).ready( function() { jQuery('#stock_shortcode_table_us').fadeIn( function() { jQuery('#stock_shortcode_table_loading').fadeOut(); jQuery('#stock_shortcode_tab_us').css('font-weight', 'bold'); }); });
Feb 14, 2017, 9:28 am EDT Purple Chips Model Company Symbol Current Price Low Valuation High Valuation GILD $67.65 $1.00 $80.00
We bought our second position in Gilead shares at $93.84 in December 2014 pilules viagra pfizer. The shares are now 31% higher at $122.80. At this juncture, the shares may go higher, but based on the historical valuation range we are satisfied that this is high enough given the volatile nature of the bio-pharma industry.
This is the second time that we’ve delivered outsized returns on GILD, having closed out a +41.0% position just a few months prior back in August 2014.
HIGH VALUATION IN GILEAD SCIENCES AT $USD 122.80 (GILD-US) HALF POSITION
TOTAL RETURN (paid no dividends) +30.8%
PURPLE CHIPS TARGET: $120.00 POSITION SIZE: HALF (2.5) P/E: 12.8X DIV: NIL MKT CAP: $180B Cash: $2B RETURN ON CAPITAL: 125.1% EARNINGS YIELD: 10.0% 5 YR EPS Growth rate*:17.0% P/E/G Ratio: 0.75 EPS: $9.57 2016 EST.: $11.00 2017 EST.: $11.86
*Blended growth rate= 2/3 historical (5yrs), 1/3 forward.